查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018681

非鴉片類鎮痛貼市場：2026-2032年全球市場預測（按產品類型、技術、藥物類型、應用、最終用戶和分銷管道分類）

Non-opioid Pain Patches Market by Product Type, Technology, Drug Type, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，非鴉片類止痛貼市場價值將達到 8.9706 億美元，到 2026 年將成長至 10.2429 億美元，到 2032 年將達到 21.4046 億美元，年複合成長率為 13.22%。

主要市場統計數據
基準年 2025 8.9706億美元
預計年份：2026年 1,024,290,000 美元
預測年份 2032 21.4046億美元
複合年成長率 (%) 13.22%

非オピオイド經皮吸収型鎮痛パッチのエコシステムを形作る臨床的ニーズ、技術的進歩、および戦略的課題を明らかにする経営層向け概要

非鴉片類鎮痛貼片市場正日趨成熟，這得益於藥物創新、先進材料科學和不斷發展的臨床實踐的融合。隨著臨床醫生和患者尋求局部、不含鴉片類藥物的替代療法來應對急性和慢性疼痛途徑，新型經皮給藥系統正日益受到關注。黏合劑化學、微加工技術和微創給藥機制的同步進步，正在提高藥物的生物利用度，並提供比傳統局部製劑更穩定的治療效果。

本報告詳細概述了技術、臨床和給藥創新融合如何重塑非鴉片類經皮鎮痛策略及其在醫療保健專業人員中的應用。

非鴉片類鎮痛貼片領域正經歷著一場變革，這得益於遞送技術、黏合劑科學和實證臨床應用等方面的進步。微針陣列（包括可溶性和固體形式）正從學術原型階段走向大規模生產，使得以往受皮膚滲透性限制的藥物分子能夠經皮遞送。同時，丙烯酸酯、水凝膠和矽膠等黏合劑平台也在不斷發展，力求在藥物相容性和患者舒適度之間取得平衡，從而有助於提高患者在急性和慢性疾病治療中的用藥依從性。

2025年に施行された米国の関税措置が、經皮療法のサプライチェーンのレジリエンス、籌資策略、および製造上の意思決定にどのような影響を与えているかに関するエビデンスに基づく分析

美國2025年實施的關稅政策，為經皮吸收貼片生產所需的醫療設備供應鏈帶來了明顯的摩擦，包括原料採購和零件進口。影響聚合物、黏合劑前驅物、電子感測器模組和專用微針製造設備的關稅調整，迫使製造商重新評估與供應商和生產地點的關係。為此，一些公司優先考慮關鍵材料的近岸採購，選擇替代材料來源，並加速垂直整合，以降低成本波動和前置作業時間風險。

黏合劑の化学的特性、投与形態、臨床適応症、エンドユーザーチャネル、および薬剤負荷量の選択を、開発および商業化の道筋と結びつける、セグメンテーションに基づく精緻な觀點

細分市場洞察闡明了產品開發、監管策略和市場進入計劃如何與多樣化的患者需求和醫療環境相契合。在考慮黏合劑技術時，黏合劑、水凝膠和矽酮黏合劑在皮膚耐受性、藥物相容性和佩戴持續時間方面的差異至關重要，每種黏合劑都需要獨特的生物相容性測試和供應鏈考慮。基於應用的細分市場區分了急性疼痛和慢性疼痛黏合劑。在急性疼痛應用情境中，術後疼痛和運動傷害疼痛尤其重要，因此快速起效和易於移除是優先考慮的因素。另一方面，在慢性疼痛治療​​中，例如關節炎和神經病變疼痛，持續藥物釋放、長期耐受性和患者依從性則更為重要。

詳細的區域評估說明了關鍵區域的不同法規結構、支付方趨勢和臨床基礎設施如何影響部署和商業化策略。

區域趨勢影響整個非鴉片類貼片市場的投資重點、監管路徑和策略夥伴關係。在美洲，完善的臨床基礎設施和新型鎮痛藥的高接受率為醫院和診所採用這些藥物創造了有利條件；然而，報銷談判和採購流程需要提供量身定做的證據材料，以證明其療效和實際效用。該地區的供應鏈考量強調可追溯性和合規性，因此製造商通常會將生產和最終組裝地點設置在更靠近終端市場的地方，以控制前置作業時間和關稅風險。

對競爭格局進行策略概述，重點在於闡述智慧財產權、夥伴關係、製造能力和證據生成如何決定非鴉片類經皮吸收領域的領導地位。

非鴉片類鎮痛貼片市場的競爭格局呈現出兩極化的特點：既有成熟的製藥和醫療設備公司拓展經皮解決方案，也有專注於微針平台和黏合劑創新技術的專業Start-Ups。主要企業優先考慮整合策略，將專有的給藥技術、可靠的臨床證據和可擴展的生產能力結合。與微針形狀、儲液囊密封方法和黏合劑化學成分相關的智慧財產權組合對於保持差異化優勢以及在許可和合作談判中佔據主導地位至關重要。

為製造商和相關人員制定可操作的策略挑戰，以加快產品分銷、加強供應鏈，並將臨床證據與支付方參與和商業化相結合。

產業領導企業應制定一套綜合藍圖，在科學差異化和切實可行的上市時間之間取得平衡。優先開發與預期臨床應用相符的黏合劑和遞送平台。例如，對於需要長期佩戴的慢性疾病，應選擇水凝膠或矽基黏合劑；對於短期急性疾病，則應選擇丙烯酸酯系統。投資於能夠產生療效比較和患者報告結局 (PRO) 數據的臨床項目，並透過與大型外科中心和運動醫學診所的早期合作，建立引人注目的真實世界數據 (REW)。

採用透明、嚴謹的混合方法研究途徑，將臨床訪談和供應鏈訪談與監管、專利和產品文件的技術審查結合。

本執行摘要的研究採用了混合方法，重點在於一手臨床數據和嚴謹的技術審查。一手研究包括對疼痛專家、採購經理、法規事務專家和生產專家進行結構化訪談，以了解實際限制、推廣應用促進因素和採購行為。這些研究結果與對同行評審的臨床文獻、已發布的監管文件、產品標籤和專利資訊披露的專項審查進行了交叉比對，以確保有關黏合劑化學成分、微針技術和儲液器結構的各項技術聲明均基於檢驗的公開文件。

明確結論將非鴉片類經皮療法的實際實施途徑與技術能力、臨床證據和操作準備的需求連結起來。

總之，非鴉片類鎮痛貼片展現出巨大的治療和商業性潛力，而這取決於技術創新、臨床效用和營運韌性的完美結合。微針技術的進步、多樣化的黏合劑化學成分以及儲庫結構的改進，正在擴展可有效治療急性和慢性疼痛的經皮方案的範圍。成功進入市場需要建立可靠的臨床證據、建立能夠適應貿易政策和原料成本波動的靈活且具有韌性的供應鏈，以及向保險公司和醫療保健系統提供清晰的價值提案。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESGとサステナビリティ分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 非鴉片類鎮痛貼市場：依產品類型分類

  • 矩陣補丁
  • 微針貼片
    • 可溶解微針
    • 固體微針
  • 水庫補丁
    • 凝膠儲液器
    • 液體儲層

第9章 非鴉片類鎮痛貼片市場：依技術分類

  • 丙烯酸黏合劑
  • ハイドロゲル系黏合劑
  • 矽膠黏合劑

第10章 非鴉片類鎮痛貼片市場（依藥物類型分類）

  • 辣椒素
  • Lidocaine
  • 非類固醇消炎劑

第11章 非鴉片類鎮痛貼市場：依應用領域分類

  • 急性疼痛
    • 術後疼痛
    • 運動傷害引起的疼痛
  • 慢性疼痛
    • 關節炎
    • 神經性疼痛

第12章 非鴉片類鎮痛貼市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院
    • 私立醫院
    • 公立醫院

第13章 非鴉片類鎮痛貼市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
    • 非處方藥
    • 處方箋

第14章 非鴉片類鎮痛貼市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 非鴉片類鎮痛貼片市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 非鴉片類鎮痛貼市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國非鴉片類止痛貼市場

第18章：中國非鴉片類鎮痛貼市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Endo International plc
  • Haw Par Corporation Limited
  • Hikma Pharmaceuticals PLC
  • Hisamitsu Pharmaceutical Co., Inc.
  • Hyloris Pharmaceuticals Ltd.
  • IBSA Institut Biochimique SA
  • Johnson & Johnson Services, Inc.
  • Kaleo, Inc.
  • Mallinckrodt Pharmaceuticals plc
  • Medherant Ltd
  • Medtronic plc
  • Mylan NV
  • Novartis AG
  • Perrigo Company plc
  • Purdue Pharma LP
  • Sorrento Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Upsher-Smith Laboratories, Inc.
  • Veridian Healthcare LLC
  • Viatris Inc.
Product Code: MRR-AD36CD897D7B

The Non-opioid Pain Patches Market was valued at USD 897.06 million in 2025 and is projected to grow to USD 1,024.29 million in 2026, with a CAGR of 13.22%, reaching USD 2,140.46 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 897.06 million
Estimated Year [2026] USD 1,024.29 million
Forecast Year [2032] USD 2,140.46 million
CAGR (%) 13.22%

An executive introduction that clarifies clinical needs, technological advancements, and strategic imperatives shaping the non-opioid transdermal pain patch ecosystem

The non-opioid pain patch landscape is maturing at the intersection of pharmaceutical innovation, advanced materials science, and evolving clinical practice. Novel transdermal systems are gaining traction as clinicians and patients seek localized, opioid-sparing alternatives that address both acute and chronic pain pathways. Concurrent advances in adhesive chemistries, microfabrication, and minimally invasive delivery mechanisms are enabling improved drug bioavailability and more consistent therapeutic profiles compared with older topical formats.

Clinicians are increasingly prioritizing products that demonstrate predictable pharmacokinetics, lower systemic exposure, and compatibility with existing care pathways. Meanwhile, manufacturers are aligning product development with patient-centered design considerations such as wearability, skin tolerability, and ease of administration outside clinical settings. As a result, strategic decisions now hinge on integrating clinical evidence, regulatory clarity, and supply chain resilience. The remainder of this executive summary synthesizes these forces, highlighting the pivotal technology shifts, regulatory and trade headwinds, segmentation-driven opportunities, and pragmatic recommendations that industry leaders can deploy to translate technical promise into commercial and clinical impact.

A detailed synthesis of the converging technology, clinical, and delivery innovations that are reshaping non-opioid transdermal analgesic strategies and provider adoption

The landscape for non-opioid pain patches is undergoing transformative shifts driven by converging advances in delivery technologies, adhesive science, and evidence-based clinical adoption. Microneedle arrays, including dissolvable and solid variants, are moving beyond academic prototypes toward scalable manufacturing, enabling transdermal access to molecules previously restricted by skin permeability. At the same time, adhesive platforms such as acrylic, hydrogel, and silicone formulations are evolving to balance drug compatibility with patient comfort, thereby improving adherence in both acute and chronic care settings.

Concurrently, product design is differentiating across matrix, microneedle, and reservoir configurations with attention to reservoir formulations in both gel and liquid forms. These form factors allow more precise dosing control and prolonged release profiles, which in turn reduce the need for systemic analgesics. Clinical pathways are adapting as hospitals, clinics, and home-care providers integrate patches into multimodal pain protocols, emphasizing postoperative and sports-related acute pain as well as chronic indications such as arthritis and neuropathic pain. In addition, digital enablement-ranging from adherence sensors to integration with electronic health records-amplifies the potential to monitor outcomes and support reimbursement conversations. Taken together, these shifts create a more differentiated competitive landscape where clinical validation and manufacturing scale are decisive.

An evidence-based analysis of how 2025 United States tariff measures are affecting supply chain resilience, procurement strategies, and manufacturing decisions for transdermal therapies

United States tariff policy enacted in 2025 has introduced measurable friction across medical device supply chains, raw-material sourcing, and component imports that underpin transdermal patch manufacturing. Tariff adjustments affecting polymers, adhesive precursors, electronic sensor modules, and specialized microneedle production equipment have prompted manufacturers to reassess supplier relationships and production footprints. In response, some firms are prioritizing nearshoring of critical inputs, qualifying alternative material sources, and accelerating vertical integration to buffer cost variability and lead-time risk.

Beyond direct input cost implications, tariffs have influenced commercial decisions such as inventory strategies and contract terms with original equipment manufacturers. Procurement teams are increasingly negotiating long-term supplier agreements to stabilize unit costs and protect production schedules. Regulatory filings and quality control processes have also been affected, as manufacturers revalidate components when suppliers change. Moreover, tariffs have had an indirect effect on innovation timelines by altering capital allocation; companies weighing investments in automation, cleanroom expansion, or microneedle tooling now factor trade policy into capital planning. Ultimately, the tariff environment underscores the importance of supply chain agility, robust supplier qualification programs, and scenario-based cost modeling when bringing new non-opioid patch technologies to market.

A nuanced segmentation-driven perspective that links adhesive chemistry, delivery formats, clinical indications, end-user channels, and drug payload choices to development and commercialization pathways

Segmentation insights reveal how product development, regulatory strategy, and go-to-market planning must align with diverse patient needs and care settings. When considering adhesive technology, distinctions among Acrylic Adhesive, Hydrogel Adhesive, and Silicone Adhesive matter for skin tolerability, drug compatibility, and wear-time performance, each demanding unique biocompatibility testing and supply chain considerations. Application segmentation separates acute and chronic pain pathways; acute use cases emphasize postoperative pain and sports injury pain where rapid onset and ease of removal are priorities, whereas chronic care targets such as arthritis and neuropathic pain focus on sustained delivery, long-term tolerability, and patient adherence.

Product type differentiation between Matrix Patch, Microneedle Patch, and Reservoir Patch drives divergent development priorities. Microneedle options-differentiated into Dissolvable Microneedle and Solid Microneedle approaches-introduce distinct regulatory and manufacturing constraints related to biodegradation and device classification, while Reservoir Patch variants with Gel Reservoir or Liquid Reservoir architectures require rigorous control of drug stability and release kinetics. End-user segmentation across Clinics, Home Care, and Hospitals, with Hospitals further categorized into Private Hospitals and Public Hospitals, informs training, inventory management, and reimbursement pathways. Finally, distribution dynamics across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, with Retail Pharmacy subdivided into Over-The-Counter and Prescription channels, influence labeling, packaging, and patient education strategies. Drug payload considerations among Capsaicin, Lidocaine, and Nonsteroidal Anti-Inflammatory Drug compounds further refine clinical positioning, as each molecule has distinct safety, contraindication, and monitoring profiles that shape labeling and commercialization tactics.

An in-depth regional assessment explaining how differing regulatory frameworks, payer dynamics, and clinical infrastructures in key geographies influence adoption and commercialization strategies

Regional dynamics are shaping investment priorities, regulatory pathways, and strategic partnerships across the non-opioid patch landscape. In the Americas, established clinical infrastructure and high adoption rates of novel analgesic modalities create fertile ground for hospital and clinic uptake, yet reimbursement negotiations and procurement processes require tailored evidence packages that demonstrate comparative effectiveness and real-world utility. Supply chain considerations in this region emphasize traceability and regulatory compliance, with manufacturers often locating production or final assembly closer to end markets to manage lead times and tariff exposure.

Europe, Middle East & Africa presents a heterogeneous regulatory environment where country-specific clinical requirements and reimbursement frameworks necessitate flexible regulatory strategies and localized payer engagement. Collaborative pilot programs with hospital networks can accelerate adoption in centers of excellence, while partnerships with regional distributors help navigate complex import and procurement rules. Asia-Pacific encompasses both advanced markets with sophisticated clinical ecosystems and emerging markets with constrained healthcare budgets. In high-income economies within the region, innovation adoption is driven by clinical leadership and private payers, whereas in emerging markets, manufacturers must optimize cost, supply chain logistics, and simplified training to achieve meaningful penetration. Across all regions, regulatory clarity, clinician education, and demonstrable patient outcomes remain vital to scaling non-opioid patch use.

A strategic profile of the competitive landscape highlighting how IP, partnerships, manufacturing capacity, and evidence generation determine leadership in the non-opioid transdermal sector

Competitive dynamics within the non-opioid pain patch sector are characterized by a mix of established pharmaceutical and device firms expanding into transdermal solutions, alongside specialized startups focusing on microneedle platforms and adhesive innovation. Leading organizations are prioritizing integrated strategies that combine proprietary delivery technologies with robust clinical evidence packages and scalable manufacturing capabilities. Intellectual property portfolios around microneedle geometries, reservoir sealing methods, and adhesive chemistries are central to maintaining differentiation and command licensing or partnership negotiations.

Strategic collaborations between device manufacturers, contract development and manufacturing organizations, and clinical research networks are increasingly common as they accelerate time to clinic while managing capital intensity. In parallel, companies that control key components-such as specialized medical-grade polymers and microfabrication tooling-gain leverage in supplier negotiations and can influence industry standards. New entrants tend to focus on niche clinical indications or unique delivery modalities to establish proof points, whereas incumbent players deploy broader commercialization networks and payer engagement expertise. Across the spectrum, success hinges on harmonizing regulatory strategy, manufacturing scale-up, and post-market surveillance to build clinician confidence and support long-term adoption.

Actionable strategic imperatives for manufacturers and stakeholders to accelerate adoption, strengthen supply chains, and align clinical evidence with payer engagement and commercialization execution

Industry leaders should pursue an integrated roadmap that balances scientific differentiation with pragmatic go-to-market execution. Prioritize development of adhesive and delivery platforms that match the intended clinical use; for example, select hydrogel or silicone adhesives for long-wear chronic indications while favoring acrylic systems for short-duration acute applications. Invest in clinical programs that generate comparative effectiveness and patient-reported outcome data, with early collaborations in high-volume surgical centers and sports medicine clinics to create compelling real-world evidence.

From an operational perspective, diversify supply chains for critical inputs and qualify secondary suppliers to mitigate tariff and geopolitical risks. Explore nearshore manufacturing or regional partnerships to reduce lead times and simplify regulatory filings. Build flexible production lines that can accommodate matrix, reservoir, and microneedle formats to capture multiple therapeutic niches. Engage payers early with health economic models and adherence data to support coverage decisions, and design packaging and labeling strategies that reflect the intended distribution channel-whether hospital pharmacy, online pharmacy, or retail channels requiring OTC or prescription classification. Finally, establish post-market surveillance protocols and digital adherence tools to collect outcomes that reinforce value propositions for clinicians and payers alike.

A transparent and rigorous mixed-methods research approach combining primary clinical and supply chain interviews with technical review of regulatory, patent, and product documentation

The research synthesis underpinning this executive summary used a mixed-methods approach that emphasizes primary clinical input and rigorous technical review. Primary research included structured interviews with pain specialists, procurement leaders, regulatory affairs professionals, and manufacturing experts to capture practical constraints, adoption drivers, and procurement behaviors. These insights were triangulated with a targeted review of peer-reviewed clinical literature, public regulatory filings, product labeling, and patent disclosures to ensure technical assertions about adhesive chemistries, microneedle technologies, and reservoir architectures are grounded in verifiable public materials.

Operational analyses incorporated supplier mapping, component qualification pathways, and manufacturing scale considerations derived from interviews with contract manufacturing organizations and quality leaders. Trade policy impacts were evaluated through analysis of tariff schedules, customs classifications relevant to polymer and device components, and case studies of firms that adjusted sourcing strategies. Throughout the research process, quality control measures such as respondent verification, source triangulation, and methodological transparency were applied to minimize bias and enhance the reliability of conclusions. The resulting insights are intended to inform strategic planning, clinical program design, and commercial execution without relying on proprietary market-sizing assumptions.

A decisive conclusion that ties technological capabilities, clinical evidence needs, and operational readiness to practical adoption pathways for non-opioid transdermal therapies

In summary, non-opioid pain patches represent a compelling therapeutic and commercial opportunity contingent on harmonizing technological innovation with clinical utility and operational resilience. Advances in microneedle technologies, diverse adhesive chemistries, and reservoir architectures are expanding the range of transdermal solutions that can effectively treat both acute and chronic pain indications. Successful market entry depends on generating robust clinical evidence, building flexible and resilient supply chains that can respond to trade-policy and input-cost volatility, and engaging payers and health systems with clear value propositions.

Going forward, stakeholders that align product design with specific clinical pathways, invest in scalable manufacturing and quality systems, and nurture strategic partnerships across distribution channels will be best positioned to translate technical innovation into sustained clinical adoption. The collective movement toward opioid-sparing pain management provides an encouraging clinical backdrop, but converting that potential into routine practice requires disciplined execution across regulatory, commercial, and operational domains. This report's insights aim to guide those decisions with practical, evidence-informed recommendations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-opioid Pain Patches Market, by Product Type

  • 8.1. Matrix Patch
  • 8.2. Microneedle Patch
    • 8.2.1. Dissolvable Microneedle
    • 8.2.2. Solid Microneedle
  • 8.3. Reservoir Patch
    • 8.3.1. Gel Reservoir
    • 8.3.2. Liquid Reservoir

9. Non-opioid Pain Patches Market, by Technology

  • 9.1. Acrylic Adhesive
  • 9.2. Hydrogel Adhesive
  • 9.3. Silicone Adhesive

10. Non-opioid Pain Patches Market, by Drug Type

  • 10.1. Capsaicin
  • 10.2. Lidocaine
  • 10.3. Nonsteroidal Anti-Inflammatory Drug

11. Non-opioid Pain Patches Market, by Application

  • 11.1. Acute Pain
    • 11.1.1. Postoperative Pain
    • 11.1.2. Sports Injury Pain
  • 11.2. Chronic Pain
    • 11.2.1. Arthritis
    • 11.2.2. Neuropathic Pain

12. Non-opioid Pain Patches Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals
    • 12.3.1. Private Hospitals
    • 12.3.2. Public Hospitals

13. Non-opioid Pain Patches Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy
    • 13.3.1. Over-The-Counter
    • 13.3.2. Prescription

14. Non-opioid Pain Patches Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Non-opioid Pain Patches Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Non-opioid Pain Patches Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Non-opioid Pain Patches Market

18. China Non-opioid Pain Patches Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Astellas Pharma Inc.
  • 19.6. Bayer AG
  • 19.7. Boehringer Ingelheim International GmbH
  • 19.8. Endo International plc
  • 19.9. Haw Par Corporation Limited
  • 19.10. Hikma Pharmaceuticals PLC
  • 19.11. Hisamitsu Pharmaceutical Co., Inc.
  • 19.12. Hyloris Pharmaceuticals Ltd.
  • 19.13. IBSA Institut Biochimique SA
  • 19.14. Johnson & Johnson Services, Inc.
  • 19.15. Kaleo, Inc.
  • 19.16. Mallinckrodt Pharmaceuticals plc
  • 19.17. Medherant Ltd
  • 19.18. Medtronic plc
  • 19.19. Mylan N.V.
  • 19.20. Novartis AG
  • 19.21. Perrigo Company plc
  • 19.22. Purdue Pharma L.P.
  • 19.23. Sorrento Therapeutics, Inc.
  • 19.24. Sun Pharmaceutical Industries Ltd.
  • 19.25. Teva Pharmaceutical Industries Ltd.
  • 19.26. Upsher-Smith Laboratories, Inc.
  • 19.27. Veridian Healthcare LLC
  • 19.28. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-OPIOID PAIN PATCHES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NON-OPIOID PAIN PATCHES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 223. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 224. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 228. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 229. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 259. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 262. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 263. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 267. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 268. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 270. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 275. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 276. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 280. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 281. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 283. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)